Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Quarter to Quarter Aggressive Growth Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (5038)	2/27/2004 11:54:34 AM
From: - with a K	Read Replies (1) \| Respond to of 6932

Jack, what do you make of ADLR's move? stockcharts.com[h,a]waclyiay[pc20!b50!f][vc60][iut!Ub14!Lc20]&pref=G NEW YORK, Feb 24 (Reuters) - Adolor Corp. (NasdaqNM:ADLR - News) on Tuesday said its post-surgical bowel disorder treatment was given fast track status by the U.S. Food and Drug Administration, sending its shares up more than 7 percent. The "fast track" review, granted by the FDA, is designated for products intended to treat serious or life-threatening conditions and/or those with unmet medical needs. The agency will review data on the treatment as soon as it is presented rather than waiting for all the data to be submitted. Adolor's drug Entereg treats postoperative ileus, a condition in which bowel function is impaired following abdominal surgery, often as a side effect of the common use of opioids for pain relief.